The rapid rise of CCTA represents one of cardiology’s biggest ongoing trends, but most primary care providers are still not embracing a CT-first strategy.

The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan. 

The company's AI-powered CCTA assessments have already been used to help manage more than 400,000 heart patients around the world.

Aspartame, the artificial sweetener commonly found in diet sodas and sugar-free snacks, may do significant harm to a person’s cardiovascular system.

Sotagliflozin, a dual SGLTI and SGLT2 inhibitor, can significantly reduce the risk of adverse cardiovascular events in patients with type 2 diabetes, CKD and additional cardiovascular risk factors, according to a new study of more than 10,000 patients. 

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.

These findings show that opportunistic imaging could go a long way toward making more patients aware of the cardiovascular risks they face—all without requiring additional scans to be performed. 

Cardiologists have warned for years that healthy adults with no family history of CVD should not be taking low-dose aspirin every day—but as the saying goes, old habits die hard.